Merck 1Q: Januvia meets CVOT goals; Keytruda ready to go in NSCLC

Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.